Park's differentiated business model and lean cost structure allow it to deliver quality care at accessible prices. This helps unlock mass-market volumes that maximize asset utilization, creating a flywheel of profitability and optimized return ratios.
Leveraging its technocrat promoters' expertise and cluster-based regional strategy, Park has steadfastly become the secondlargest chain by bed capacity in North India. The management's demonstrated execution prowess and ability to turn around acquisitions (often sick units) are validated with such units contributing ~62% to FY26 EBITDA.
This agility allows for rapid scale without compromising on capex discipline. With a robust pipeline (~2,200 beds identified; ~60% of FY26 capacity) and a strategic roadmap to enter high-demand, underpenetrated markets such as UP, we expect Park to clock 24%/23% revenue/EBITDA CAGR over FY26-29. Strong balance sheet (net cash of Rs2bn), healthy cash conversion (FY26 OCF/EBITDA: 74%), and improving working capital cycle should drive a re-rating.
Outlook
We initiate coverage on Park Medi World (Park) with BUY and Mar-27E TP of Rs350 (37% upside), based on 21x Mar-28E EBITDA (in line with sector average).


No comments:
Post a Comment